Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
prostaglandin/vähk
Link salvestatakse lõikelauale
Leht 1 alates 72 tulemused
Method of treating neoplastic cells with prostaglandin and radiation treatment or prostaglandin and platinum-based anti-tumor agents
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to a method of treating neoplastic cells with prostaglandin. More particularly, a therapeutically effective amount of ionizing radiation required to treat a neoplasm in a subject can be reduced by administering
Prostaglandin-F2 alpha receptor modulators and uses thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention generally relates to prostaglandin-F2 alpha (PGF2.alpha.) receptor modulation and uses thereof for the treatment of conditions associated with PGF2.alpha. receptor activity such as preterm labor and colorectal cancer.
BACKGROUND OF THE INVENTION
Preterm
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and that such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have
Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin E2, method of production thereof and use thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF ART
The invention concerns polysubstituted pyrimidine derivatives showing the effect of a simultaneous decrease in the production of nitric oxide (NO) and prostaglandin E2 (PGE2) and their use as medicaments.
BACKGROUND ART
The specialized literature provides reliable data that long-term
Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF INVENTION
This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin D2 (PGD2) level or
Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF INVENTION
This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin D2 (PGD2) level or
Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
This invention provides a method for identifying compounds potentially useful for the treatment and prevention of pre-cancerous and cancerous lesions in mammals. This application is a continuation of U.S. patent application Ser. No. 08/866,027 to Piazza et al. Filed May
Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
This application claims priority under 35 U.S.C. .sctn.120 to U.S. Patent App. Ser. Nos. 08/866,027 and 09/046,739, filed May 30, 1997 and Mar. 24, 1998, respectively.
This invention relates to the use of one or more forms of phosphodiesterase type 2 ("PDE2") and
Composition and method for cancer chemoprevention
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
1. Field
Methods and compositions for cancer chemoprevention. In particular, methods and compositions that inhibit growth and/or development of tumors.
2. Background
Prostaglandins are members of a group of lipid compounds derived enzymatically from fatty acids and are found in nearly all
Use of diterpene compound as a therapeutic agent of inflammation, immune disease or cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to a novel use of diterpene compounds as a therapeutic agent for the treatment of inflammatory disease, immunological disease or cancer.
BACKGROUND OF THE INVENTION
Exposure of human tissue or cells to harmful stimuli such as lipopolysaccharide
Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
This invention relates to a prostaglandin E2 receptor 4 (EP4) antagonist for use in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer. The method for treatment of NASH-associated liver cancer comprises administering any one of Compound A, Compound B or
Selective EP4 receptor antagonistic substance for treatment of cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This application is a U.S. national stage of International Application No. PCT/JP2010/057114 filed Apr. 22, 2010.
TECHNICAL FIELD
This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general
Selective EP4 receptor antagonistic substance for treatment of cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof (hereafter it is sometimes called
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
